¼¼°èÀÇ Àν¶¸° Àü´Þ ½Ã½ºÅÛ ½ÃÀå
Insulin Delivery Systems
»óǰÄÚµå : 1513887
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2024³â 07¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 272 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,144,000
PDF & Excel (Single User License) help
PDF & Excel º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. ÆÄÀÏ ³» ÅØ½ºÆ®ÀÇ º¹»ç ¹× ºÙ¿©³Ö±â´Â °¡´ÉÇÏÁö¸¸, Ç¥/±×·¡ÇÁ µîÀº º¹»çÇÒ ¼ö ¾ø½À´Ï´Ù. Àμâ´Â 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 24,434,000
PDF & Excel (Global License to Company and its Fully-owned Subsidiaries) help
PDF & Excel º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ ¹× 100% ÀÚȸ»çÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÏ½Ç ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â 1Àδç 1ȸ °¡´ÉÇϸç, Àμ⹰ÀÇ ÀÌ¿ë¹üÀ§´Â ÆÄÀÏ ÀÌ¿ë¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

Àν¶¸° Àü´Þ ½Ã½ºÅÛ ¼¼°è ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 168¾ï ´Þ·¯¿¡ ´ÞÇÒ Àü¸Á

2023³â 134¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â Àν¶¸° Àü´Þ ½Ã½ºÅÛ ¼¼°è ½ÃÀåÀº 2023-2030³â ºÐ¼® ±â°£ µ¿¾È ¿¬Æò±Õ 3.3% ¼ºÀåÇÏ¿© 2030³â¿¡´Â 168¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ÀÌ º¸°í¼­¿¡¼­ ºÐ¼®ÇÏ´Â ºÎ¹® Áß ÇϳªÀÎ ÁÖ»ç±â´Â CAGR 3.4%¸¦ ±â·ÏÇÏ¿© ºÐ¼® ±â°£ Á¾·á ½ÃÁ¡¿¡ 70¾ï ´Þ·¯¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Ææ ºÎ¹®ÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 4.3%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀå 36¾ï ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 5.8%·Î ¼ºÀå Àü¸Á

¹Ì±¹ Àν¶¸° Àü´Þ ½Ã½ºÅÛ ½ÃÀåÀº 2023³â 36¾ï ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2030³â±îÁö 34¾ï ´Þ·¯ÀÇ ½ÃÀå ±Ô¸ð¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2023-2030³â ºÐ¼® ±â°£ µ¿¾È 5.8%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ´Ù¸¥ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ª ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ µ¿¾È °¢°¢ 0.6%¿Í 4.0%ÀÇ CAGRÀ» ±â·ÏÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ ¿¬Æò±Õ 1.4%ÀÇ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Àν¶¸° Àü´Þ ½Ã½ºÅÛ - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ

Àν¶¸° Àü´Þ ½Ã½ºÅÛÀº Àü ¼¼°è ¼ö¹é¸¸ ¸íÀÌ ¾Î°í ÀÖ´Â ¸¸¼º ÁúȯÀÎ ´ç´¢º´À» °ü¸®ÇÏ´Â µ¥ ÇʼöÀûÀÎ ¿ä¼ÒÀÔ´Ï´Ù. Àν¶¸° Àü´Þ ½Ã½ºÅÛÀº Ç÷´ç Á¶Àý¿¡ ÇÊ¿äÇÑ È£¸£¸óÀÎ Àν¶¸°À» Á¦¾îµÇ°í È¿À²ÀûÀÎ ¹æ½ÄÀ¸·Î Åõ¿©Çϵµ·Ï ¼³°èµÇ¾ú½À´Ï´Ù. Àν¶¸° Àü´Þ ½Ã½ºÅÛ¿¡´Â ÁÖ»ç±â, Àν¶¸° Ææ, Àν¶¸° ÆßÇÁ, ÈíÀÔÇü Àν¶¸°°ú °°Àº »õ·Î¿î ¹æ¹ý µî ´Ù¾çÇÑ Á¾·ù°¡ ÀÖ½À´Ï´Ù. °¢ ½Ã½ºÅÛÀº ÆíÀǼº, Á¤È®¼º, »ç¿ëÀÚ °æÇè Ãø¸é¿¡¼­ ¼­·Î ´Ù¸¥ ÀåÁ¡À» °¡Áö°í ÀÖ½À´Ï´Ù. ¿¹¸¦ µé¾î, Àν¶¸° ÆæÀº ¹Ì¸® ä¿öÁ® ÀÖ°í ÈÞ´ë°¡ °£ÆíÇϱ⠶§¹®¿¡ ¸¹Àº ȯÀڵ鿡°Ô Àαâ ÀÖ´Â ¼±ÅÃÀÌ µÇ°í ÀÖ½À´Ï´Ù. Àν¶¸° ÆßÇÁ´Â ü³» ÀÚ¿¬ Àν¶¸° ºÐºñ¿¡ °¡±î¿î Áö¼ÓÀûÀÎ Àν¶¸° ºÐºñ°¡ °¡´ÉÇÏ¿© ƯÈ÷ Á¦ 1 Çü ´ç´¢º´ ȯÀÚ¿¡°Ô À¯ÀÍÇÕ´Ï´Ù. ÀÇ·á ±â¼úÀÇ ¹ßÀü°ú ȯÀÚÀÇ ¿ä±¸¿¡ ´ëÇÑ ±íÀº ÀÌÇØ·Î ÀÎÇØ »óȲÀº ²÷ÀÓ¾øÀÌ ÁøÈ­Çϰí ÀÖ½À´Ï´Ù.

±â¼ú Çõ½ÅÀº Àν¶¸° Àü´Þ ½Ã½ºÅÛÀÇ ¹ßÀü¿¡ Å« ¿øµ¿·ÂÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÃֽŠÀν¶¸° ÆßÇÁ´Â Áö¼ÓÀû Ç÷´ç ¸ð´ÏÅ͸µ(CGM) ÅëÇÕ, ÀÚµ¿ Àν¶¸° Åõ¿©(AID), ½º¸¶Æ®Æù ¿¬°á°ú °°Àº ÷´Ü ±â´ÉÀ» °®Ãß°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº º¸´Ù Á¤È®ÇÏ°í °³ÀÎÈ­µÈ ´ç´¢º´ °ü¸®¸¦ °¡´ÉÇÏ°Ô ÇÏ¿© ÀúÇ÷´ç À§ÇèÀ» ÁÙÀ̰í Àü¹ÝÀûÀÎ Ç÷´ç Á¶ÀýÀ» °³¼±ÇÒ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, º¹¿ë·®À» ÃßÀûÇÏ°í ¾Ë¸²À» Á¦°øÇÒ ¼ö ÀÖ´Â ½º¸¶Æ® Àν¶¸° ÆæÀÇ °³¹ßÀº º¹¾à ¼øÀÀµµ ¹× Åõ¾à Á¤È®µµ ¹®Á¦¸¦ ÇØ°áÇÏ´Â µ¥ µµ¿òÀÌ µÇ°í ÀÖ½À´Ï´Ù. ÈíÀÔÇü Àν¶¸°Àº ÁÖ»ç ´ë½Å ºñħ½ÀÀû ´ë¾ÈÀ» Á¦°øÇÔÀ¸·Î½á ÁÖ»ç¹Ù´ÃÀ» ½È¾îÇϴ ȯÀڵ鿡°Ô ¾îÇÊÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, Àΰø ÃéÀå ½Ã½ºÅÛÀ̶ó°íµµ ºÒ¸®´Â Æó¼âÇü ·çÇÁ ½Ã½ºÅÛ¿¡ ´ëÇÑ ¿¬±¸µµ ÁøÇà ÁßÀ̸ç, ȯÀÚÀÇ °³ÀÔÀ» ÃÖ¼ÒÈ­ÇÏ´Â ¿ÏÀü ÀÚµ¿ Àν¶¸° Åõ¿© ¼Ö·ç¼ÇÀ» ±¸ÇöÇÏ´Â °ÍÀ» ¸ñÇ¥·Î Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ±â¼ú Çõ½ÅÀº ´ç´¢º´ ȯÀÚÀÇ »îÀÇ ÁúÀ» Çâ»ó½Ãų »Ó¸¸ ¾Æ´Ï¶ó ´ç´¢º´ Ä¡·áÀÇ »õ·Î¿î Ç¥ÁØÀÌ µÇ°í ÀÖ½À´Ï´Ù.

Àν¶¸° Àü´Þ ½Ã½ºÅÛ ½ÃÀåÀÇ ¼ºÀåÀº ´ç´¢º´ À¯º´·ü Áõ°¡, ±â¼ú ¹ßÀü, ´ç´¢º´ °ü¸®¿¡ ´ëÇÑ ÀÎ½Ä Áõ°¡ µî ¿©·¯ °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ºñ¸¸°ú ÁÂ½Ä »ýȰ½À°ü µîÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ ´ç´¢º´, ƯÈ÷ Á¦ 2Çü ´ç´¢º´ÀÇ À¯º´·üÀÌ Áõ°¡ÇÔ¿¡ µû¶ó È¿À²ÀûÀÌ°í »ç¿ëÇϱ⠽¬¿î Àν¶¸° Àü´Þ ¼Ö·ç¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Å©°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ±â¼úÀÇ ¹ßÀüÀ¸·Î ÀÎÇØ ÀÌ·¯ÇÑ ½Ã½ºÅÛÀº ´õ¿í ½±°í È¿°úÀûÀ¸·Î »ç¿ëÇÒ ¼ö ÀÖ°Ô µÇ¾î ´õ ¸¹Àº ȯÀÚµéÀ» ²ø¾îµéÀ̰í ÀÖ½À´Ï´Ù. ¸ð¹ÙÀÏ ¾Û°ú Ŭ¶ó¿ìµå ±â¹Ý µ¥ÀÌÅÍ °ü¸®¿Í °°Àº µðÁöÅÐ Çコ ±â¼úÀÇ ÅëÇÕÀº ȯÀÚÀÇ Âü¿©¿Í Ä¡·á ÇÁ·ÎÅäÄÝ Áؼö¸¦ °­È­Çϰí ÀÖ½À´Ï´Ù. ¼ÒºñÀÚ Çൿµµ º¯È­Çϰí ÀÖÀ¸¸ç, ÆíÀǼº°ú ÃÖ¼Òħ½À¼º ¿É¼Ç¿¡ ´ëÇÑ ¼±È£µµ°¡ ³ô¾ÆÁö¸é¼­ ½º¸¶Æ® ÆæÀ̳ª ÈíÀÔÇü Àν¶¸°°ú °°Àº Çõ½ÅÀûÀÎ Àü´Þ ¹æ¹ýÀÇ Ã¤ÅÃÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ´ç´¢º´ Ä¡·á ÀÎÇÁ¶ó ±¸ÃàÀ» À§ÇÑ Á¤ºÎ Áö¿ø Á¤Ã¥ ¹× ÀÌ´Ï¼ÅÆ¼ºê°¡ ½ÃÀå ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù. °æÀï ȯ°æÀº ÇÏÀÌÅ×Å© ±â¾÷°ú ÀÇ·á ¼­ºñ½º Á¦°øÀÚÀÇ Çù¾÷ÀÌ µÎµå·¯Áö°Ô ³ªÅ¸³ª°í ÀÖÀ¸¸ç, ÀÌ´Â Çõ½Å°ú ½ÃÀå ħÅõ¸¦ ´õ¿í °¡¼ÓÈ­Çϰí ÀÖ½À´Ï´Ù. Àü¹ÝÀûÀ¸·Î, Àν¶¸° Àü´Þ ½Ã½ºÅÛ ½ÃÀåÀº Àα¸ µ¿Çâ, ±â¼ú ¹ßÀü, ÁøÈ­Çϴ ȯÀÚ ¼±È£µµÀÇ Á¶ÇÕ¿¡ ÈûÀÔ¾î Å©°Ô È®´ëµÉ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

Á¶»ç ´ë»ó ±â¾÷ ¿¹½Ã(ÃÑ 32°³»ç)

¸ñÂ÷

Á¦1Àå Á¶»ç ¹æ¹ý

Á¦2Àå ÁÖ¿ä ¿ä¾à

Á¦3Àå ½ÃÀå ºÐ¼®

Á¦4Àå °æÀï

ksm
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global Insulin Delivery Systems Market to Reach US$16.8 Billion by 2030

The global market for Insulin Delivery Systems estimated at US$13.4 Billion in the year 2023, is expected to reach US$16.8 Billion by 2030, growing at a CAGR of 3.3% over the analysis period 2023-2030. Syringes, one of the segments analyzed in the report, is expected to record a 3.4% CAGR and reach US$7.0 Billion by the end of the analysis period. Growth in the Pens segment is estimated at 4.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$3.6 Billion While China is Forecast to Grow at 5.8% CAGR

The Insulin Delivery Systems market in the U.S. is estimated at US$3.6 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$3.4 Billion by the year 2030 trailing a CAGR of 5.8% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 0.6% and 4.0% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 1.4% CAGR.

Insulin Delivery Systems - Key Trends and Drivers

Insulin delivery systems are a critical component in the management of diabetes, a chronic condition affecting millions of people worldwide. These systems are designed to administer insulin, a hormone necessary for regulating blood glucose levels, in a controlled and efficient manner. There are various types of insulin delivery systems, including syringes, insulin pens, insulin pumps, and newer methods like inhalable insulin. Each of these systems offers different advantages in terms of convenience, precision, and user experience. Insulin pens, for example, are prefilled and easy to carry, making them a popular choice for many patients. Insulin pumps provide continuous insulin delivery, closely mimicking the body’s natural insulin release, which is particularly beneficial for individuals with type 1 diabetes. The landscape of insulin delivery systems is continuously evolving, driven by advancements in medical technology and a deeper understanding of patient needs.

Technological innovation has been a significant driver in the advancement of insulin delivery systems. Modern insulin pumps are now equipped with advanced features such as continuous glucose monitoring (CGM) integration, automated insulin delivery (AID), and smartphone connectivity. These advancements allow for more precise and personalized diabetes management, reducing the risk of hypoglycemia and improving overall glycemic control. Additionally, the development of smart insulin pens, which can track doses and provide reminders, is helping to address issues related to adherence and dosing accuracy. The introduction of inhalable insulin offers a non-invasive alternative to injections, appealing to patients who are needle-averse. Furthermore, research into closed-loop systems, also known as artificial pancreas systems, is ongoing, with the goal of creating fully automated insulin delivery solutions that require minimal patient intervention. These innovations are not only improving the quality of life for diabetes patients but are also setting new standards in diabetes care.

The growth in the insulin delivery systems market is driven by several factors, including the increasing prevalence of diabetes, technological advancements, and a growing awareness of diabetes management. The rising incidence of diabetes particularly type 2 diabetes, due to factors such as obesity and sedentary lifestyles, has significantly expanded the demand for efficient and user-friendly insulin delivery solutions. Technological advancements have made these systems more accessible and effective, attracting a broader patient base. The integration of digital health technologies, such as mobile apps and cloud-based data management, is enhancing patient engagement and adherence to treatment protocols. Consumer behavior is also shifting, with a greater emphasis on convenience and minimally invasive options, driving the adoption of innovative delivery methods like smart pens and inhalable insulin. Additionally, supportive government policies and initiatives aimed at improving diabetes care infrastructure are facilitating market growth. The competitive landscape is marked by collaborations between tech companies and healthcare providers, further accelerating innovation and market penetration. Overall, the insulin delivery systems market is poised for significant expansion, propelled by a combination of demographic trends, technological progress, and evolving patient preferences.

Select Competitors (Total 32 Featured) -

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

III. MARKET ANALYSIS

IV. COMPETITION

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â